Get notified when ABBV files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Earnings-quality Divergence (worsened) — Net income rose 285.2% while operating income rose only 31.4%; the bottom-line gain is driven by a smaller below-the-line deduction, not operational improvement.
AbbVie Q2 revenue +10.2% to $17.0B; net income +285.2% to $3.61B on non-operating factors
Filed August 3, 2026 · Period ending June 30, 2026 · Compared to 10-Q Aug 4, 2025 · ~1 min read
Key Changes
-
high
Net income rose 285.2% to$3.61B, but the jump came from a smaller below-the-line deduction (non-operating/other +$1.2B, income tax -$49.0M, noncontrolling interest +$0 = +$1.1B), not operations.
MD&A: Earnings verify on EDGAR → -
high
AbbVie agreed to acquire Apogee Therapeutics for ~$10.9B in cash, with a new $10.0B term loan facility arranged; deal expected to close in Q3 2026.
Notes: Acquisitions verify on EDGAR → -
high
U.S. pricing agreement grants a three-year tariff and price-mandate exemption in exchange for $100B in U.S. R&D and manufacturing investment; Botox selected for Medicare price negotiation starting 2028.
MD&A: Regulatory verify on EDGAR →
2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (SPWH 10-Q) is open in full — no account needed.
Partner
Trade ABBV commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Sep 3, 2026 · How we verify